



Department of Health and Human Services

Public Health Service

Food and Drug Administration
Rockville, MD 20857

SEP 30 2009

Re: Macroplastique Implants
Docket Nos. FDA-2008-E-0091
FDA-2008-E-0099
FDA-2008-E-0204

The Honorable David J. Kappos
Under Secretary of Commerce for Intellectual Property
Director of the United States Patent and Trademark Office
Mail Stop Hatch-Waxman PTE
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Director Kappos:

This is in regard to the patent term extension applications for U.S. Patent Nos. 5,258,028; 5,336,263; and 5,571,182 filed by Uroplasty, Inc. under 35 U.S.C. § 156. The patents claim Macroplastique Implants, premarket application (PMA) P040050.

In the February 11, 2009, issue of the Federal Register (74 Fed. Reg. 6901), the Food and Drug Administration published its determination of this product's regulatory review period, as required under 35 U.S.C. § 156(d)(2)(A). The notice provided that on or before August 10, 2009, 180 days after the publication of the determination, any interested person could file a petition with FDA under 35 U.S.C. § 156(d)(2)(B)(i) for a determination of whether the patent term extension applicant acted with due diligence during the regulatory review period.

The 180-day period for filing a due diligence petition pursuant to this notice has expired and FDA has received no such petition. Therefore, FDA considers the regulatory review period determination to be final.

Please let me know if we can provide further assistance.

Sincerely yours,

Jane A. Axelrad
Associate Director for Policy
Center for Drug Evaluation and Research

USPTO – Patent Nos. 5,258,028; 5,336,263; and 5,571,182
Uroplasty, Inc.
Macroplastique Implants
Page 2

cc: Amy J. Hoffman
KAGAN BINDER, PLLC
221 Main Street North, Suite 200
Stillwater, MN 55082